56
Participants
Start Date
October 19, 2015
Primary Completion Date
February 15, 2021
Study Completion Date
February 15, 2021
nal-IRI
5 fluorouracil
Leucovorin
Oxaliplatin
Box Hill Hospital, Lilydale
Flinders Medical Centre, Bedford Park
St. John of God Health Care - Subiaco, Subiaco
Roswell Park Cancer Institute, Buffalo
Gettysburg Cancer Center, Gettysburg
Maryland Oncology Hematology, Silver Spring
Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC), Madrid
Hospital Universitario de Fuenlabrada, Fuenlabrada
Medical Group of the Carolinas - Spartanburg Regional Health Services, Spartanburg
Greenville Health System, Greenville
Mayo Clinic Cancer Center, Jacksonville
University of Miami, Miami
University of South Alabama, Mobile
University of South Alabama - Mobile, Mobile
Oncology/Hematology Care Clinical Trials, LLC, Cincinnati
Mayo Clinic Cancer Center - Rochester, Rochester
Oncology Hematology West PC dba Nebraska, Omaha
University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center, Oklahoma City
Texas Oncology Methodist Dallas Cancer Center, Dallas
Texas Oncology-Fort Worth 12 Ave, Fort Worth
Houston Methodist Cancer Center and Institute of Academic Medicine, Houston
Oncology Consultants - Houston, Houston
Texas Oncology, P.A., San Antonio
Joe Arrington Cancer Research and Treatment Center - Lubbock, Lubbock
University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion, Aurora
Mayo Clinic Hospital, Phoenix
Arizona Center for Cancer Care, Avondale
US Oncology - Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas
UCLA Hematology Oncology - Ventura, Los Angeles
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange
Willamette Valley Cancer Institute & Research Center, Eugene
Eastern Maine Medical Cancer Care, Brewer
Lahey Hospital & Medical Center, Burlington
Holy Name Medical Center, Teaneck
Hospital General Universitario de Elche, Elche
Hospital Universitario Vall d'Hebron, Barcelona
Lead Sponsor
Ipsen
INDUSTRY